From policy pushes to FDA milestones and billion-dollar deals, this week reminded us just how dynamic healthtech has become.
Here are some healthtech news we came across this week:
India AI Impact Summit 2026: SAHI, BODH & Big Healthtech Signals
The India AI Impact Summit (15th–20th) turned into a major moment for India’s healthtech ecosystem. Among the headline announcements were the launch of the SAHI and BODH initiatives by the Government of India, both aimed at accelerating AI adoption across healthcare.
SAHI: Strategy for AI in Healthcare for India
- A national framework to ensure AI tools in healthcare are safe, ethical, and compliant
- Focuses on validation, accountability, and patient data protection
- Aims to build trust before AI solutions are deployed in real-world clinical settings
BODH: Benchmarking Open Data Platform for Health AI
- A structured platform to test and benchmark health AI models on standardised datasets
- Enables evidence-based evaluation before adoption
- Supports transparency and performance comparison across AI solutions
This is big. Because healthcare AI now must be validated, ethical, explainable, and accountable before it reaches patients. And India is building the rails for that.
While detailed frameworks are still unfolding, the event signals India’s transition from AI ambition to AI implementation. Expect stronger public-private collaboration, responsible AI frameworks, and structured deployment in healthcare systems.
We also saw global AI players like Anthropic exploring partnerships in Indian healthcare, another sign that India is becoming a serious testbed for AI-led healthcare innovation.
The event was massive, with 100+ global CEOs and founders attending it. This includes high profile leaders like Sam Altman (OpenAI), Sunder Pichai (Google), among others.
There’s a lot to unpack here: policy design, funding pathways, clinical AI adoption models. We’ll break this down in detail next week. Stay tuned.
Medtronic secures FDA approval for StealthStation Innovation
Medtronic this week received U.S. Food and Drug Administration (FDA) clearance for its Stealth AXiS™ surgical system. A major advancement in spine surgery technology.
This is a first-of-its-kind integrated platform that combines pre-operative planning, real-time navigation, and robotic assistance into one intelligent system, helping surgeons plan and execute complex procedures with more precision.
Key details:
- The system is cleared for spinal procedures in the U.S., and its modular design means it can be used in hospitals and ambulatory surgery centers without needing multiple separate technologies.
- A standout feature is LiveAlign segmental tracking, which lets surgeons visualize spinal motion and adjustments in real time, reducing dependence on repeated X-rays during surgery.
- Medtronic says this platform lays the groundwork for future expansion into other areas, like cranial and ENT procedures, pending additional clearances.
The approval strengthens Medtronic’s position in image-guided spine surgery.
Carbon Health files for bankruptcy
Carbon Health has filed for Chapter 11 bankruptcy protection in the U.S., marking one of the biggest restructurings in digital primary care this year.
At its peak, the hybrid care startup had:
- Raised $600+ million in funding
- Reached a $3.3 billion valuation (2021)
- Expanded to nearly 100 clinics across the U.S.
However, rising operating costs, slower post-pandemic telehealth demand, and profitability challenges put pressure on the business.
The company has secured ~$19.5 million in debtor-in-possession (DIP) financing to continue operations during restructuring and is exploring a potential sale or debt restructuring plan.
A clear reminder: scale without sustainable margins is risky in today’s healthtech market.
Breath Diagnostics gets FDA Breakthrough Device Designation
Breath Diagnostics, Inc. received FDA Breakthrough Device Designation for its OneBreath™ platform, designed to assess pneumonia risk before surgery.
The platform uses breath analysis to help identify patients at risk of post-operative pulmonary complications, a major cause of morbidity and hospital costs.
Breakthrough designation doesn’t mean approval, but it does fast-track development and regulatory review. If successful, this could mark another step toward non-invasive, rapid diagnostics powered by advanced sensing technology.
Hims & Hers acquires Eucalyptus in $1.15 Bn deal
In one of the week’s biggest deals, Hims & Hers Health, Inc. is acquiring Australia-based Eucalyptus for up to $1.15 billion. This marks one of the biggest global telehealth expansions this year.
Key numbers & highlights:
- Hims & Hers will pay $240M cash upfront at closing. Remaining value tied to deferred payments + performance earnouts (through 2029).
- Eucalyptus brings $450 Mn+ annual revenue run-rate and has 775,000+ customers across multiple countries.
- The acquisition expands Hims & Hers footprint into Australia, UK, Germany, Japan, and Canada
- The deal is expected to close mid-2026 after clearing all the pending approvals.
This move transforms Hims & Hers from a U.S.-focused telehealth brand into a serious global digital health platform, and signals continued consolidation in consumer healthcare.
If healthtech is your space, follow All Health Tech for updates that go beyond the headlines.
We’re the exclusive HealthTech Alpha Partners in India! Reach out if you’re looking for deeper market intelligence or strategic perspectives.
